U.S. market Closed. Opens in 2 hours 14 minutes

RGEN | Repligen Corporation Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 128.91 - 139.17
52 Week Range 113.50 - 211.13
Beta 0.92
Implied Volatility 50.39%
IV Rank 48.12%
Day's Volume 710,907
Average Volume 698,817
Shares Outstanding 56,006,500
Market Cap 7,779,302,850
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 1986-04-29
Valuation
Profitability
Growth
Health
P/E Ratio -463.00
Forward P/E Ratio 57.33
EPS -0.30
1YR Price Target 250.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 1,783
Country USA
Website RGEN
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
RGEN's peers: AXON, BDX, COO, ISRG, RMD, MMSI, ICUI, WST, HOLX, TFX, HAE, ANGO, ATR, NVST, STAA
*Chart delayed
Analyzing fundamentals for RGEN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very good and Health is strong. For more detailed analysis please see RGEN Fundamentals page.

Watching at RGEN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RGEN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙